Covidien Announces FDA Approval For Its Generic Myocardial Perfusion Imaging Kit
Sep 30th 2008Drug InformationMRI / PET / Ultrasound
Covidien (NYSE: COV, BSX: COV), a leading global provider of healthcare products, announced that the U.S. Food and Drug Administration (FDA) has granted approval for the Company’s Abbreviated New Drug Application (ANDA) for its Kit for the Preparation of Technetium Tc 99m Sestamibi Injection. Covidien’s generic product is pharmaceutically equivalent to Cardiolite®1, a myocardial perfusion imaging agent used for detecting coronary artery disease.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
